Sarpatwari A, Lu Z, Russo M, Zakoul H, Lee SB, Toyserkani GA, Zhou EH, LaCivita C, Hyatt Hawkins Shaw K, Dal Pan GJ, Kesselheim AS - JAMA Network Open
Clozapine, an effective therapy for treatment-resistant schizophrenia, had a risk evaluation and mitigation strategy (REMS) program in place to manage the risk of agranulocytosis. In a survey of nearly 200 physicians, two-thirds viewed the REMS program positively, though some physicians called for more educational materials and raised concerns about delays in patient access due to required laboratory testing.
VIEW SOURCE
Daval CJR, Kesselheim AS - STAT
Mulsant SS, Kesselheim AS, Naci H - Journal of Cancer Policy
Avorn J - MedPage Today